Original ArticleMutations of RNA splicing factors in hematological malignancies

- Mutant splicing factors play a crucial role in developing the hematological and solid cancers.
- Mutant splicing factors are resulting in the modification of cellular transcriptome and proteome of the cancer cell, hence acting like oncogenes.
- Targeting functions of splicing factors appear to be a novel approach for cancer therapeutics.

Systematic large-scale cancer genomic studies have produced numerous significant findings. These studies have not only revealed new cancer-promoting genes, but they also have identified cancer-promoting functions of previously known “housekeeping” genes. These studies have identified numerous mutations in genes which play a fundamental role in nuclear precursor mRNA splicing. Somatic mutations and copy number variation in many of the splicing factors which participate in the formation of multiple spliceosomal complexes appear to play a role in many cancers and in particular in myelodysplastic syndromes (MDS). Mutated proteins seem to interfere with the recognition of the authentic splice sites (SS) leading to utilization of suboptimal alternative splicing sites generating aberrantly spliced mRNA isoforms. This short review is focusing on the function of the splice factors involved in the formation of splicing complexes and potential mechanisms which affect usage of the authentic splice site recognition.